Get started
ANAPTYSBIO INC COM USD0.001ANAPTYSBIO INC COM USD0.001ANAPTYSBIO INC COM USD0.001

ANAPTYSBIO INC COM USD0.001

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

0HFQ chart


Full chart

0HFQ upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪602.18 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−6.3 USD
Net income (FY)
‪−163.62 M‬ USD
Revenue (FY)
‪17.16 M‬ USD
Shares float
‪25.82 M‬
Beta (1Y)
1.76

Employees


Employees (FY)
117
Change (1Y)
+21 +21.88%
Revenue / Employee (1Y)
‪146.64 K‬ USD
Net income / Employee (1Y)
‪−1.40 M‬ USD

About AnaptysBio, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Daniel R. Faga
Website
anaptysbio.com
Headquarters
San Diego
Founded
2005
FIGI
BBG00JVRN5Q9
AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

0HFQ news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 0HFQ is 20.1 USD — it has decreased by −9.95% in the past 24 hours. Watch ANAPTYSBIO INC COM USD0.001 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange ANAPTYSBIO INC COM USD0.001 stocks are traded under the ticker 0HFQ.
0HFQ stock has fallen by −33.96% compared to the previous week, the month change is a −42.72% fall, over the last year ANAPTYSBIO INC COM USD0.001 has showed a 19.69% increase.
We've gathered analysts' opinions on ANAPTYSBIO INC COM USD0.001 future price: according to them, 0HFQ price has a max estimate of 90.00 USD and a min estimate of 30.00 USD. Watch 0HFQ chart and read a more detailed ANAPTYSBIO INC COM USD0.001 stock forecast: see what analysts think of ANAPTYSBIO INC COM USD0.001 and suggest that you do with its stocks.
0HFQ reached its all-time high on Mar 5, 2018 with the price of 128.6 USD, and its all-time low was 9.6 USD and was reached on Nov 8, 2019. View more price dynamics on 0HFQ chart.
See other stocks reaching their highest and lowest prices.
0HFQ stock is 11.55% volatile and has beta coefficient of 1.76. Track ANAPTYSBIO INC COM USD0.001 stock price on the chart and check out the list of the most volatile stocks — is ANAPTYSBIO INC COM USD0.001 there?
Today ANAPTYSBIO INC COM USD0.001 has the market capitalization of ‪602.18 M‬, it has decreased by −31.16% over the last week.
Yes, you can track ANAPTYSBIO INC COM USD0.001 financials in yearly and quarterly reports right on TradingView.
ANAPTYSBIO INC COM USD0.001 is going to release the next earnings report on Nov 7, 2024. Keep track of upcoming events with our Earnings Calendar.
0HFQ earnings for the last quarter are −1.71 USD per share, whereas the estimation was −1.04 USD resulting in a −64.30% surprise. The estimated earnings for the next quarter are −1.65 USD per share. See more details about ANAPTYSBIO INC COM USD0.001 earnings.
ANAPTYSBIO INC COM USD0.001 revenue for the last quarter amounts to ‪10.97 M‬ USD, despite the estimated figure of ‪22.76 M‬ USD. In the next quarter, revenue is expected to reach ‪8.21 M‬ USD.
0HFQ net income for the last quarter is ‪−46.66 M‬ USD, while the quarter before that showed ‪−43.94 M‬ USD of net income which accounts for −6.20% change. Track more ANAPTYSBIO INC COM USD0.001 financial stats to get the full picture.
No, 0HFQ doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 5, 2024, the company has 117.00 employees. See our rating of the largest employees — is ANAPTYSBIO INC COM USD0.001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ANAPTYSBIO INC COM USD0.001 EBITDA is ‪−152.65 M‬ USD, and current EBITDA margin is −901.65%. See more stats in ANAPTYSBIO INC COM USD0.001 financial statements.
Like other stocks, 0HFQ shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ANAPTYSBIO INC COM USD0.001 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ANAPTYSBIO INC COM USD0.001 technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ANAPTYSBIO INC COM USD0.001 stock shows the sell signal. See more of ANAPTYSBIO INC COM USD0.001 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.